The renin-angiotensin system (RAS) remains a cornerstone of cardiovascular and renal physiology, orchestrating vital aspects of blood pressure regulation and fluid-electrolyte balance. At the heart of ...

In a recent study posted to the medRxiv* preprint server, researchers conducted an umbrella review and meta-analysis of the renin-angiotensin-aldosterone system (RAAS) inhibitors' impact on ...

Angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor antagonists have become an important tool for the treatment of hypertension and its cardiovascular complications. Inhibition ...

"I feel better, but my mind isn't the same." Four years after the height of the COVID-19 pandemic, such comments are still heard regularly in many medical practices in South Africa. What began as a ...

Please provide your email address to receive an email when new articles are posted on . RAS blockers had similar mortality benefit by race in patients with HFrEF. RAS blockers improved HF ...

In patients with mild or moderate chronic kidney disease, renin–angiotensin system inhibitors have improved outcomes, but less evidence supports their use in advanced CKD. New research findings are ...

In this randomized trial, the discontinuation of renin–angiotensin system inhibitors in patients with advanced chronic kidney disease did not lead to a significant between-group difference in the long ...

Cost-effectiveness of NALIRIFOX compared to other first-line treatments for metastatic pancreatic cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This ...